<DOC>
	<DOCNO>NCT01412060</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety cariprazine relative placebo prevention relapse symptom patient schizophrenia .</brief_summary>
	<brief_title>Cariprazine Relative Placebo Prevention Relapse Symptoms Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients provide informed consent prior study specific procedure Patients currently meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) criteria schizophrenia confirm Patients normal physical examination , laboratory , vital sign , and/ ECG Diagnosis schizophrenia minimum 1 year Visit 1 Positive Negative Syndrome Scale ( PANSS ) total score great equal 70 less equal 120 Visit 1 Visit 2 Negative serum Bhuman chorionic gonadotropin ( BhCG ) pregnancy test ( applies female patient childbearing potential ) Body mass index 18 40kg/m2 , inclusive Patients currently meet DSMIVTR criterion schizoaffective disorder , schizophreniform disorder , bipolar I II know suspected borderline antisocial personality disorder DSMIVTR axis II disorder Patients first episode Psychosis Treatmentresistant schizophrenia last 2 year Positive result blood alcohol test urine drug screen prohibit medication At imminent risk injure self others cause significant damage property Suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic Disorder</keyword>
</DOC>